Aspirin as an Ultraviolet (UV) Protectant in Human Subjects at Risk for Melanoma

• Status: Recruiting
• Trial end date: 2027-01-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a phase II placebo-controlled intervention trial assessing aspirin (ASA) as a UV protectant in patients at risk for melanoma.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Utah
• Treatments: Aspirin; Protective Agents

Criteria

Inclusion Criteria:

• Must have at least 2 nevi (each >5 mm diameter) not clinically suspicious for melanoma that can be biopsied.

• Must be older than age 18.

• Must be able to receive informed consent and sign an approved consent form that conforms to federal and institutional guidelines.

Exclusion Criteria:

• The patient cannot speak / understand English or Spanish.

• The patient is pregnant or breastfeeding.

• The patient is a prisoner, critically or mentally ill, or otherwise incapacitated or considered vulnerable.

• The patient has history of allergic reaction to ASA.

• The patient has history of severe asthma.

• The patient has been taking ASA or any NSAID in the past 2 weeks.

• The patient has been taking a blood thinner in the past 2 weeks.

• The patient has history of bleeding disorder.

• The patient has history of peptic ulcer disease.

• The patient has had recent intense UV exposure in the past month.